IN THE SPOTLIGHT (Paris/Healthtech/Investment) - Lauxera Capital Partners closes its Lauxera Growth II fund at €520M, exceeding its initial target of €500M and doubling the size of its first vehicle. This growth equity fund targets 12 to 15 investmen

WORLD(Australia/Medtech/Urology) - NinaMED launches with $13.75M in financing led by SPRIM Global Investments to develop and commercialize the NiNA System, a non‑invasive, at‑home, drug‑free neuromodulation device for overactive bladder (OAB), under

WORLD(United States/Biotech/Microbiome & IO) - Kanvas Biosciences closes a $48M Series A co‑led by DCVC and Lions Capital, followed by the Gates Foundation, ATHOS KG, Germin8, Ki Tua Fund and Pangaea Ventures. This round brings total funding to $78M

EUROPE(United Kingdom/Biotech/Oncology) - Cytospire Therapeutics closes an oversubscribed Series A of £61M ($83M) led by 4BIO Capital followed by Servier Ventures (first deal from its corporate fund), British Business Bank, Sound Bioventures, Criteri

WORLD(United States/Biotech/CNS gene therapy) - Latus Bio closes a $97M Series A, including a $43M extension led by 8VC, with support from existing investors (DCVC Bio, BioAdvance, Benjamin Franklin Technology Partners, Modi Ventures, Gaingels, Hatc

WORLD(United States/Biotech/Proteomics) – Alamar Biosciences completes its IPO on Nasdaq (ticker ALMR), with shares issued at $17 and an initial listing at $22.6, valuing the precision proteomics company at around $1.5 billion. Driven by its propriet

WORLD(China/Biotech/Pain) – Haisco Pharmaceutical signs an exclusive license agreement with AbbVie, including an upfront payment of $30M and milestone payments of up to $715M, plus royalties on future sales. The agreement covers the development, manu

Ecosystème

“Today, the question for a biopharma is no longer just: ‘What are you developing?’, but ‘How do you create value, from concept to patient?’”. Unlike a scientific or purely technical book, the book "The Thriving Biopharma Business " co-written by Alai

VCFrance

Innovation in health is no longer merely a scientific or economic issue: it has become a field of strategic confrontation. The United States, whichremain the leading financial and biotechnological power, are experiencing structural weakening, caught

ESSENTIEL

EcosystèmeFrance

WORLD(United States/Biotech/Neurology) – Cognito Therapeutics closes an oversubscribed $105M Series C led by Morningside Ventures, IAG Capital Partners and Starbloom Capital, followed by New Vintage, Apollo Health Ventures and Benvolio Group. The fun

HEADLINE FRANCE: LILLE IN THE SPOTLIGHT(United States/Biotech/Infectious diseases) – ILiAD Biotechnologies closes an oversubscribed $115M Series B round led by RA Capital Management with participation from Janus Henderson Investors, BNP Paribas Asset

WORLD(United States/Biotech/Oncology & Immuno-inflammation) — Third Arc Bio completes a $52M extension of its Series A, bringing the total round to $217M, to accelerate its immunology portfolio and further advance oncology programs into the clinic. T